Suprachoroidal Administration in Subjects With Metastases to the Choroid
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAura Biosciences
About this trial
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Eligibility criteria
Qualifiers
Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor.
Have at least one Metastases to the Choroid in the study eye
Disqualifiers
Active ocular infection or disease.
Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.
Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment
Trial design
Treatments tested in this trial
- AU-011
- SCS Microinjector
- Laser
Treatment groups
24 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Locations
10California
Byers Eye Institute at Stanford University94303, Palo Alto United States
Florida
Bascom Palmer Eye Institute33136, Miami United States
Massachusetts
Massachusetts Eye and Ear02114, Boston United States
Michigan
Kellogg Eye Center48105, Ann Arbor United States
Sponsors and collaborators
Aura Biosciences
Lead sponsor
Source ClinicalTrials.gov